MedTrace Logo

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

NCT00482729 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1246

Last updated 2017-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficacy and safety of an investigational treatment for type 2 diabetes mellitus.

Conditions

Interventions

DRUG

sitagliptin phosphate (+) metformin hydrochloride

sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.

DRUG

metformin

metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-19
Primary Completion
2008-11-03
Completion
2009-04-27

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00482729 on ClinicalTrials.gov